Health Condition 1: R739- Hyperglycemia, unspecified
Conditions
Interventions
None listed
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Patients having age between 18 to 50 years of either sex Signs and symptoms of Prameha Purvarupavastha Impaired fasting glucose (Fasting plasma glucose 100-125 mg/dl) Impaired PPBS 2 hours (PP2BS 140-200 mg/dl) Impaired HbA1C (HBAIC 5.7-6.4 %) Patients willing to give their consent to participate in the study
Exclusion criteria
Exclusion criteria: Age below 18 and above 50 years Systemic illness like active tuberculosis carcinoma or endocrine disorders like Cushing syndrome Hypothyroidism Patient having the past history of M.I. & Unstable Angina or Clinical Features of congestive cardiac failure. Patients having advanced renal or liver disorder. Patients having fasting blood sugar = 125 mg/dl or PP2BS level = 200 mg/dl Patient having history of acute inflammatory bowel disease or chronic pancreatitis Patients on cortico-steroids or recent history of treatment with cortico-steroids Major psychiatric illness
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected that the trial drugs will break the pathogenesis of pre-diabetes and thus will be effective in the management of pre-diabetesTimepoint: 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| The drug will improve the quality of life and thus will act as disease-modifying agent for pre-diabetes.Timepoint: 8 weeks | — |
Countries
India
Contacts
ITRA,Jamnagar